Developer docs
API playgroundTry for free, no card

Search company profiles

Pulmatrix

Full company profile

uuid0005d68

Namestring
Pulmatrix
Legal namestring
Pulmatrix, Inc.
Websiteurl
pulmatrix.com
Company typeenum
Public
Founded yearint
2003
Descriptiontext

Pulmatrix is a clinical-stage biopharmaceutical company incorporated in Delaware and headquartered in Framingham, Massachusetts. Historically, the company developed inhaled therapeutic products using its proprietary iSPERSE platform, targeting respiratory diseases and acute migraine; clinical assets included PUR1900 (inhaled antifungal, previously partnered with Cipla), PUR3100 (Phase 2-ready acute migraine), and PUR1800 (respiratory). All clinical development is currently on hold as management pursues asset out-licensing and a reverse merger transaction. In March 2026 Pulmatrix announced a definitive agreement to acquire Eos SENOLYTIX in a reverse merger, with a concurrent $19 million private financing; on closing, the combined entity will operate as Eos SENOLYTIX on Nasdaq under ticker 'EOSX' and pivot to mitochondrial-targeted geropeptide therapies for aging-related diseases, with lead clinical candidate PTC-2105 for sarcopenia. Pulmatrix stockholders are expected to own approximately 6% of the post-merger company versus approximately 94% for pre-merger Eos stockholders.

Pulmatrix's revenue model has historically been licensing and collaboration-based rather than product-based: 2024 revenue of $7.8 million derived entirely from the Cipla PUR1900 collaboration, which was wound down during 2025 and drove reported 2025 revenue to $0. Going forward, the company's value-capture mechanism is asset monetization — out-licensing legacy iSPERSE programs — combined with the equity-event value of the reverse merger and accompanying private placements (including a $1 million Series B Convertible Preferred financing with an Eos affiliate in April 2026). There are no disclosed pricing models, commercial products, or active distribution channels; the company currently has 11–50 employees and a market capitalization of approximately $4.38 million as of April 2026, with $3.3 million of cash on the balance sheet as of March 31, 2026 and a Q1 2026 net loss of $1.172 million.

Short descriptiontext

Pulmatrix is a clinical-stage biopharmaceutical company that has developed inhaled therapeutics via its iSPERSE platform and is undergoing a reverse merger with Eos SENOLYTIX to pivot into mitochondrial-targeted geropeptide therapies for aging-related diseases, with the combined entity to trade on Nasdaq.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBedford, United States
HQ citystring
Bedford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
inhaled therapeutics, respiratory pharmaceuticals, acute migraine treatment, antifungal inhalation therapy, biopharmaceutical drug development
Industry1 code
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Asset Monetization/Licensing
TypeLicensing Royalties
Description

Pulmatrix is seeking to out-license or monetize its clinical assets including PUR1900, PUR3100, and PUR1800. Revenue 2025 fell to $0 compared to $7.8M in 2024, driven by wind-down of PUR1900 program collaboration with Cipla.

prnewswire.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Pulmatrix is a clinical-stage biopharmaceutical company that develops inhaled therapies using its proprietary iSPERSE dry powder delivery technology to treat respiratory diseases and acute migraine. The company's pipeline includes PUR1900 (inhaled antifungal for allergic bronchopulmonary aspergillosis), PUR3100 (acute migraine), and PUR1800 (respiratory). Pulmatrix is also pursuing a reverse merger with Eos SENOLYTIX to expand into gerotherapeutic peptides including senolytic peptides (MitoXcel) and PTC-2105.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Preclinical data shows unique muscle mass gains with PTC-2105
+1 more record
Product overview1 text field

Pulmatrix is a clinical-stage biopharmaceutical company that developed inhaled therapeutic products using its proprietary iSPERSE™ technology platform. The company has clinical assets including PUR3100 (Phase 2-ready acute migraine program), PUR1900 (inhaled antifungal, wound-down from Cipla collaboration), and PUR1800 (respiratory disease treatment). In March 2026, Pulmatrix announced a reverse merger with Eos SENOLYTIX to form a combined entity focused on gerotherapeutic peptides targeting aging-related diseases, with the merged company expected to trade on Nasdaq under ticker 'EOSX'.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Previously announced merger agreement with Cullgen was terminated on February 28, 2026 due to delays in obtaining regulatory approval from China's Securities Regulatory Commission. The merger had received stockholder approval in June 2025 but was contingent on CSRC approval that was never obtained. Cullgen subsequently chose to be acquired by Gyre Therapeutics in a $300 million all-stock deal.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

PUR1900 program collaboration with Cipla was wound down, resulting in revenue falling to zero for 2025 compared to $7.8 million for 2024.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Savara is a clinical-stage specialty pharma developing inhaled antibiotics (e.g., molgramostim, amikacin) for serious respiratory infections — directly comparable to Pulmatrix as a small, inhaled-delivery respiratory therapeutics developer.

TypeDirect peer
Description

Verona developed the inhaled COPD therapy ensifentrine (Ohtuvayre), making it a direct peer as a pulmonology specialty pharma building an inhaled commercial respiratory franchise.

TypeDirect peer
Description

Theravance commercializes inhaled respiratory products (Yupelri/revefenacin, partnered Trelegy) and is a direct peer in pulmonology specialty pharmaceuticals using innovative inhaled mechanisms.

TypeDirect peer
Description

Inhalon develops an inhaled iSPERSE-based ion-channel-targeted antimicrobial platform for respiratory infections, making it a direct peer with a closely related inhaled particle technology targeting respiratory disease.

TypeDirect peer
Description

Insmed markets Arikayce, an inhaled liposomal amikacin for refractory NTM lung infection, and has a broader inhaled respiratory pipeline — a directly comparable inhaled pulmonary specialty pharma.

TypeBroad incumbent
Description

Vectura (now owned by Philip Morris) is a long-standing inhaled drug delivery specialist that licenses its dry-powder and nebulizer platforms to pharma companies — a broad incumbent in the same inhaled delivery category Pulmatrix's iSPERSE competes within.

TypeDirect peer
Description

United Therapeutics develops and commercializes inhaled and infused therapies for pulmonary hypertension and pulmonary disease (Tyvaso, Remodulin) — a direct peer in pulmonology specialty pharma with both inhaled delivery and orphan-pulmonary indications.

TypeBroad incumbent
Description

AstraZeneca is a broad incumbent with a major respiratory franchise (Symbicort, Breztri, Fasenra, Saphnelo) and large R&D footprint, representing the scaled end of the pulmonology specialty pharma category Pulmatrix plays in.

TypeEmerging player
Description

BioAge is a clinical-stage gerotherapeutics company developing drugs that target the biology of aging, including indications in obesity and muscle wasting — directly comparable to the Eos SENOLYTIX geropeptide platform that Pulmatrix is merging into.

TypeBroad incumbent
Description

Teva has a substantial respiratory specialty and generics portfolio (ProAir, Qvar, AirDuo) and is a broad incumbent pulmonology pharma against which Pulmatrix's inhaled respiratory programs are ultimately benchmarked.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pulmatrix

Pulmatrix is a clinical-stage biopharmaceutical company that has developed inhaled therapeutics via its iSPERSE platform and is undergoing a reverse merger with Eos SENOLYTIX to pivot into mitochondrial-targeted geropeptide therapies for aging-related diseases, with the combined entity to trade on Nasdaq.

What Pulmatrix does

Pulmatrix is a clinical-stage biopharmaceutical company incorporated in Delaware and headquartered in Framingham, Massachusetts. Historically, the company developed inhaled therapeutic products using its proprietary iSPERSE platform, targeting respiratory diseases and acute migraine; clinical assets included PUR1900 (inhaled antifungal, previously partnered with Cipla), PUR3100 (Phase 2-ready acute migraine), and PUR1800 (respiratory). All clinical development is currently on hold as management pursues asset out-licensing and a reverse merger transaction. In March 2026 Pulmatrix announced a definitive agreement to acquire Eos SENOLYTIX in a reverse merger, with a concurrent $19 million private financing; on closing, the combined entity will operate as Eos SENOLYTIX on Nasdaq under ticker 'EOSX' and pivot to mitochondrial-targeted geropeptide therapies for aging-related diseases, with lead clinical candidate PTC-2105 for sarcopenia. Pulmatrix stockholders are expected to own approximately 6% of the post-merger company versus approximately 94% for pre-merger Eos stockholders.

Pulmatrix's revenue model has historically been licensing and collaboration-based rather than product-based: 2024 revenue of $7.8 million derived entirely from the Cipla PUR1900 collaboration, which was wound down during 2025 and drove reported 2025 revenue to $0. Going forward, the company's value-capture mechanism is asset monetization — out-licensing legacy iSPERSE programs — combined with the equity-event value of the reverse merger and accompanying private placements (including a $1 million Series B Convertible Preferred financing with an Eos affiliate in April 2026). There are no disclosed pricing models, commercial products, or active distribution channels; the company currently has 11–50 employees and a market capitalization of approximately $4.38 million as of April 2026, with $3.3 million of cash on the balance sheet as of March 31, 2026 and a Q1 2026 net loss of $1.172 million.

Pulmatrix firmographics

Firmographics
Name
Pulmatrix
Legal name
Pulmatrix, Inc.
Website
https://pulmatrix.com
Company type
Public
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Short description
Pulmatrix is a clinical-stage biopharmaceutical company that has developed inhaled therapeutics via its iSPERSE platform and is undergoing a reverse merger with Eos SENOLYTIX to pivot into mitochondrial-targeted geropeptide therapies for aging-related diseases, with the combined entity to trade on Nasdaq.
Ownership category
akta.pro rank

Pulmatrix industry classification

Industry
akta.pro industry
PRIMARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals

Keywords

  • Inhaled therapeutics
  • Respiratory pharmaceuticals
  • Acute migraine treatment
  • Antifungal inhalation therapy
  • Biopharmaceutical drug development

Where Pulmatrix is headquartered

Location

Headquarters

HQ city
Bedford
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Pulmatrix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Asset Monetization/Licensing: Pulmatrix is seeking to out-license or monetize its clinical assets including PUR1900, PUR3100, and PUR1800. Revenue 2025 fell to $0 compared to $7.8M in 2024, driven by wind-down of PUR1900 program collaboration with Cipla.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Pulmatrix product offering

Product offering

Core offering

Pulmatrix is a clinical-stage biopharmaceutical company that develops inhaled therapies using its proprietary iSPERSE dry powder delivery technology to treat respiratory diseases and acute migraine. The company's pipeline includes PUR1900 (inhaled antifungal for allergic bronchopulmonary aspergillosis), PUR3100 (acute migraine), and PUR1800 (respiratory). Pulmatrix is also pursuing a reverse merger with Eos SENOLYTIX to expand into gerotherapeutic peptides including senolytic peptides (MitoXcel) and PTC-2105.

Product overview

Pulmatrix is a clinical-stage biopharmaceutical company that developed inhaled therapeutic products using its proprietary iSPERSE™ technology platform. The company has clinical assets including PUR3100 (Phase 2-ready acute migraine program), PUR1900 (inhaled antifungal, wound-down from Cipla collaboration), and PUR1800 (respiratory disease treatment). In March 2026, Pulmatrix announced a reverse merger with Eos SENOLYTIX to form a combined entity focused on gerotherapeutic peptides targeting aging-related diseases, with the merged company expected to trade on Nasdaq under ticker 'EOSX'.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Preclinical data shows unique muscle mass gains with PTC-2105
  • +1 more outcomes

Companies that use Pulmatrix

Customer profile

Segments2 records

Ideal customer profiles1 record

Pulmatrix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Pulmatrix partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor.

  • Cullgen Inc.minorStrategic or Co-development Partner · 1 November 2025Previously announced merger agreement with Cullgen was terminated on February 28, 2026 due to delays in obtaining regulatory approval from China's Securities Regulatory Commission. The merger had received stockholder approval in June 2025 but was contingent on CSRC approval that was never obtained. Cullgen subsequently chose to be acquired by Gyre Therapeutics in a $300 million all-stock deal.
  • CiplaminorStrategic or Co-development PartnerPUR1900 program collaboration with Cipla was wound down, resulting in revenue falling to zero for 2025 compared to $7.8 million for 2024.

Scale indicators7 records

Recent moves6 records

Expansion highlights4 records

Pulmatrix competitors and assessment

Company assessment

Direct peers

  • Savara Inc. Savara is a clinical-stage specialty pharma developing inhaled antibiotics (e.g., molgramostim, amikacin) for serious respiratory infections — directly comparable to Pulmatrix as a small, inhaled-delivery respiratory therapeutics developer.
  • Verona Pharma: Verona developed the inhaled COPD therapy ensifentrine (Ohtuvayre), making it a direct peer as a pulmonology specialty pharma building an inhaled commercial respiratory franchise.
  • Theravance Biopharma: Theravance commercializes inhaled respiratory products (Yupelri/revefenacin, partnered Trelegy) and is a direct peer in pulmonology specialty pharmaceuticals using innovative inhaled mechanisms.
  • Inhalon Biopharma: Inhalon develops an inhaled iSPERSE-based ion-channel-targeted antimicrobial platform for respiratory infections, making it a direct peer with a closely related inhaled particle technology targeting respiratory disease.
  • Insmed Incorporated: Insmed markets Arikayce, an inhaled liposomal amikacin for refractory NTM lung infection, and has a broader inhaled respiratory pipeline — a directly comparable inhaled pulmonary specialty pharma.
  • United Therapeutics: United Therapeutics develops and commercializes inhaled and infused therapies for pulmonary hypertension and pulmonary disease (Tyvaso, Remodulin) — a direct peer in pulmonology specialty pharma with both inhaled delivery and orphan-pulmonary indications.

Broad incumbents

  • Vectura Group: Vectura (now owned by Philip Morris) is a long-standing inhaled drug delivery specialist that licenses its dry-powder and nebulizer platforms to pharma companies — a broad incumbent in the same inhaled delivery category Pulmatrix's iSPERSE competes within.
  • AstraZeneca: AstraZeneca is a broad incumbent with a major respiratory franchise (Symbicort, Breztri, Fasenra, Saphnelo) and large R&D footprint, representing the scaled end of the pulmonology specialty pharma category Pulmatrix plays in.
  • Teva Pharmaceutical Industries: Teva has a substantial respiratory specialty and generics portfolio (ProAir, Qvar, AirDuo) and is a broad incumbent pulmonology pharma against which Pulmatrix's inhaled respiratory programs are ultimately benchmarked.

Emerging players

  • BioAge Labs: BioAge is a clinical-stage gerotherapeutics company developing drugs that target the biology of aging, including indications in obesity and muscle wasting — directly comparable to the Eos SENOLYTIX geropeptide platform that Pulmatrix is merging into.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat1 record

Key risks6 records

Key highlights5 records

Customer concentration

Pulmatrix social profiles

Digital presence

Pulmatrix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pulmatrix leadership team

Management profile

Number of profiles

Profiles5 records

Pulmatrix funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pulmatrix M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pulmatrix

What does Pulmatrix do?

Pulmatrix is a clinical-stage biopharmaceutical company that develops inhaled therapies using its proprietary iSPERSE dry powder delivery technology to treat respiratory diseases and acute migraine. The company's pipeline includes PUR1900 (inhaled antifungal for allergic bronchopulmonary aspergillosis), PUR3100 (acute migraine), and PUR1800 (respiratory). Pulmatrix is also pursuing a reverse merger with Eos SENOLYTIX to expand into gerotherapeutic peptides including senolytic peptides (MitoXcel) and PTC-2105.

Is Pulmatrix a public or private company?

Pulmatrix is a public company. It is classified as public and is currently operating.

When was Pulmatrix founded?

Pulmatrix was founded in 2003. It employs 11 to 50 people.

Where is Pulmatrix based?

Pulmatrix is headquartered in Bedford, United States, in the North America region.

How does Pulmatrix make money?

One revenue line is on record: asset Monetization/Licensing.

Who are Pulmatrix's main competitors?

Direct peers on record are Savara Inc., Verona Pharma, Theravance Biopharma, Inhalon Biopharma, Insmed Incorporated and United Therapeutics. Broad incumbents are Vectura Group, AstraZeneca and Teva Pharmaceutical Industries. BioAge Labs is listed as an emerging player.

Does Pulmatrix have an API?

No public API is recorded for Pulmatrix.

What industry is Pulmatrix in?

Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Dealroom.coPulmatrix nears year-end merger with Eos as cash falls to $1.4M | Dealroom NewsPulmatrix expects to close its all-stock merger with Eos by end of November 2026, with Eos holders and financing participants owning about 94% of the combined company. Pulmatrix's cash fell to $1.4 million at quarter-end, and the deal hinges on Nasdaq approval of new shares and a reverse stock split. The transaction is Pulmatrix's route back to compliance with Nasdaq's $2.5 million stockholders' equity rule.TradingViewPulmatrix, Inc. (PULM) Anticipates Eos Merger Close in NovemberPulmatrix said its merger with Eos SENOLYTIX is anticipated to close in November, subject to Nasdaq listing approval, a reverse stock split, and other conditions. Q3 cash and equivalents fell to $1.4M from $4.1M at Dec. 31, 2025, and the company disclosed going-concern uncertainty, citing cash expected to fund operations through the anticipated closing.American Banking and Market NewsPulmatrix (PULM) Projected to Post Quarterly Earnings on ThursdayPulmatrix is expected to report Q3 2026 earnings on Thursday, November 5th, with analysts projecting a loss of $2.00 per share and revenue of $1.53 million. The company's stock opened at $1.33, and Weiss Ratings cut its rating to a sell (e+) on August 14th.The future of tradingPulmatrix Holds Special Shareholder MeetingPulmatrix shareholders approved merger-related common stock issuance and a change of control at a special meeting on October 26, 2026. The approved issuance exceeds 20% of pre-merger outstanding stock, and shareholders also authorized a reverse stock split and an increase in authorized common stock from 200 million to 250 million shares.American Banking and Market NewsPulmatrix (NASDAQ:PULM) versus Silo Pharma (NASDAQ:SILO) Financial SurveySilo Pharma and Pulmatrix are compared on profitability, valuation, and institutional ownership. Silo Pharma has higher earnings but lower revenue, while Pulmatrix trades at a lower price-to-earnings ratio. Analyst ratings for both are a sell with a score of 1.00.Defense WorldPulmatrix, Inc. (NASDAQ:PULM) Stock Short Interest Rises 174.2%Short interest in Pulmatrix rose 174.2% to 55,391 shares as of September 15th. BlackRock bought a new stake of 54,899 shares, and Weiss Ratings lowered the stock to a sell rating. The company reported a loss of $0.29 per share for the quarter.BioSpaceEos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting MitochondriaEos SENOLYTIX will present at the 17th World Congress on Targeting Mitochondria in Berlin, with CEO Kevin Slawin delivering a keynote on mitochondrial-targeted geropeptide medicine. The company's lead candidate PTC-2105 is in preclinical development for sarcopenia and sarcopenic obesity, and a proposed merger with Pulmatrix is expected to close in Q4 2026.Markets DailyPulmatrix, Inc. (NASDAQ:PULM) Sees Significant Increase in Short InterestPulmatrix's short interest surged 384.2% to 20,198 shares as of August 31, with a short-interest ratio of 1.6 days. The stock traded at $1.44, and analysts have a consensus Sell rating. Weiss Ratings cut the stock to a Sell (e+) rating on August 14.Markets DailyShort Interest in Pulmatrix, Inc. (NASDAQ:PULM) Decreases By 75.2%Pulmatrix's short interest fell 75.2% to 4,171 shares as of August 14, down from 16,792 on July 30, with 0.1% of shares short sold and a 0.5-day-to-cover ratio. Weiss Ratings downgraded the biotech from "sell (d-)" to "sell (e+)" on August 14, and shares traded down $0.01 to $1.51.Ticker ReportPulmatrix (NASDAQ:PULM) Posts Earnings Results, Beats Expectations By $1.71 EPSPulmatrix reported a quarterly loss of $0.29 per share, significantly beating the consensus estimate of a $2.00 loss by $1.71. The company's stock price declined 5.6% following the announcement despite the earnings surprise.